R1 RCM Inc. to Post Q3 2022 Earnings of $0.11 Per Share, SVB Leerink Forecasts (NASDAQ:RCM)

R1 RCM Inc. (NASDAQ:RCMGet Rating) – Equities researchers at SVB Leerink dropped their Q3 2022 earnings per share estimates for R1 RCM in a research report issued to clients and investors on Monday, May 9th. SVB Leerink analyst S. Davis now forecasts that the healthcare provider will earn $0.11 per share for the quarter, down from their prior estimate of $0.12. SVB Leerink also issued estimates for R1 RCM’s Q4 2022 earnings at $0.12 EPS, FY2022 earnings at $0.41 EPS and FY2023 earnings at $0.59 EPS.

R1 RCM (NASDAQ:RCMGet Rating) last issued its quarterly earnings results on Monday, May 9th. The healthcare provider reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). The business had revenue of $385.70 million for the quarter, compared to the consensus estimate of $384.18 million. R1 RCM had a return on equity of 29.44% and a net margin of 6.64%. R1 RCM’s revenue was up 12.6% on a year-over-year basis. During the same period in the prior year, the business posted ($2.37) earnings per share.

A number of other brokerages have also weighed in on RCM. Deutsche Bank Aktiengesellschaft decreased their target price on R1 RCM from $30.00 to $28.00 in a research report on Tuesday. Guggenheim assumed coverage on R1 RCM in a research report on Wednesday, April 13th. They set a “neutral” rating for the company. Robert W. Baird lifted their target price on R1 RCM from $29.00 to $32.00 in a research report on Thursday, March 3rd. TheStreet raised R1 RCM from a “d” rating to a “c” rating in a research report on Monday, May 9th. Finally, Zacks Investment Research downgraded R1 RCM from a “buy” rating to a “hold” rating in a report on Friday. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $29.25.

Shares of NASDAQ RCM opened at $22.52 on Thursday. The company has a quick ratio of 1.43, a current ratio of 1.54 and a debt-to-equity ratio of 2.06. The business has a fifty day simple moving average of $24.79 and a two-hundred day simple moving average of $24.49. The firm has a market cap of $6.30 billion, a PE ratio of 72.65, a price-to-earnings-growth ratio of 2.25 and a beta of 0.86. R1 RCM has a twelve month low of $18.71 and a twelve month high of $27.86.

A number of hedge funds have recently made changes to their positions in the stock. Advisor Group Holdings Inc. grew its stake in R1 RCM by 8.3% during the 3rd quarter. Advisor Group Holdings Inc. now owns 5,723 shares of the healthcare provider’s stock worth $128,000 after buying an additional 439 shares during the last quarter. Profund Advisors LLC grew its stake in R1 RCM by 4.3% during the 3rd quarter. Profund Advisors LLC now owns 11,671 shares of the healthcare provider’s stock worth $257,000 after buying an additional 485 shares during the last quarter. First Mercantile Trust Co. grew its stake in R1 RCM by 5.6% during the 3rd quarter. First Mercantile Trust Co. now owns 10,266 shares of the healthcare provider’s stock valued at $226,000 after purchasing an additional 544 shares during the last quarter. Prospera Financial Services Inc grew its stake in R1 RCM by 2.1% during the 1st quarter. Prospera Financial Services Inc now owns 27,760 shares of the healthcare provider’s stock valued at $743,000 after purchasing an additional 571 shares during the last quarter. Finally, Insight Wealth Strategies LLC grew its stake in R1 RCM by 0.6% during the 4th quarter. Insight Wealth Strategies LLC now owns 101,955 shares of the healthcare provider’s stock valued at $2,599,000 after purchasing an additional 636 shares during the last quarter. Hedge funds and other institutional investors own 41.97% of the company’s stock.

R1 RCM Company Profile (Get Rating)

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers.

See Also

Earnings History and Estimates for R1 RCM (NASDAQ:RCM)

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.